GLYSKY ™ – Powerful Dual Combination for Precise Glycemic Control
GLYSKY™ (Glimepiride + Metformin Extended-Release) delivers comprehensive, rational, and sustained glycemic control in patients with Type 2 Diabetes Mellitus by addressing multiple core pathophysiological defects simultaneously. Its complementary mechanism ensures effective control of both fasting and post-prandial glucose, resulting in superior HbA1c reduction with balanced, all-day glucose stability.
The extended-release metformin technology in GLYSKY™ provides consistent plasma levels, improved gastrointestinal tolerability, and convenient once-daily dosing, enhancing long-term patient adherence. Metformin’s insulin-sparing and weight-neutral profile counterbalances sulfonylurea-associated weight gain and helps reduce hypoglycemia risk—making GLYSKY™ a patient-friendly and durable therapy.
With its proven efficacy, cost-effectiveness, and decades-long safety profile, GLYSKY™ stands as a reliable, trusted, and premium choice for effective Type 2 diabetes management—where science meets confidence.